Trademark: 97135396
Word
PINOVA THERAPEUTICS
Status
Pending
Status Code
730
Status Date
Saturday, March 2, 2024
Serial Number
97135396
Mark Type
4000
Filing Date
Friday, November 19, 2021
Published for Opposition
Tuesday, July 18, 2023

Trademark Owner History
Pocket Naloxone Corp. - Owner At Publication

Classifications
5 pharmaceutical preparations for the treatment of opioid dependence, benzodiazepine dependence, anaphalytic shock, seizures, hypoglycemia, neurodegenerative disorders, allergies, blood pressure, acute chest pain, mastocytosis disease, pain management, anxiety, post-traumatic stress disorder, sleep disorders, hypercalcaemia, osteoporosis, migraines, hormone replacement therapy side effects, smoking cessation, nausea, motion sickness, heartburn, indigestion, acid reflux, hemophiliac bleeding, urinary incontinence, mood disorders, vitamin deficiencies, low phosphate levels, diarrhea, asthma, chronic obstructive pulmonary disease, endometriosis, and early puberty
44 medical and healthcare information services namely providing medical and healthcare information in the fields of opioid dependence, benzodiazepine dependence, anaphalytic shock, seizures, hypoglycemia, neurodegenerative disorders, allergies, blood pressure, acute chest pain, mastocytosis disease, pain management, anxiety, post-traumatic stress disorder, sleep disorders, hypercalcaemia, osteoporosis, migraines, hormone replacement therapy, smoking cessation, nausea, motion sickness, heartburn, indigestion, acid reflux, hemophiliac bleeding, urinary incontinence, mood disorders, vitamin deficiencies, low phosphate levels, diarrhea, asthma, chronic obstructive pulmonary disease, endometriosis, and early puberty
42 scientific research and development into treatments of opioid dependence, benzodiazepine dependence, anaphalytic shock, seizures, hypoglycemia, neurodegenerative disorders, allergies, blood pressure, acute chest pain, mastocytosis disease, pain management, anxiety, post-traumatic stress disorder, sleep disorders, hypercalcaemia, osteoporosis, migraines, hormone replacement therapy, smoking cessation, nausea, motion sickness, heartburn, indigestion, acid reflux, hemophiliac bleeding, urinary incontinence, mood disorders, vitamin deficiencies, low phosphate levels, diarrhea, asthma, chronic obstructive pulmonary disease, endometriosis, and early puberty; pharmaceutical research and development into treatments of opioid dependence, benzodiazepine dependence, anaphalytic shock, seizures, hypoglycemia, neurodegenerative disorders, allergies, blood pressure, acute chest pain, mastocytosis disease, pain management, anxiety, post-traumatic stress disorder, sleep disorders, hypercalcaemia, osteoporosis, migraines, hormone replacement therapy, smoking cessation, nausea, motion sickness, heartburn, indigestion, acid reflux, hemophiliac bleeding, urinary incontinence, mood disorders, vitamin deficiencies, low phosphate levels, diarrhea, asthma, chronic obstructive pulmonary disease, endometriosis, and early puberty; pharmaceutical research and development into treatments of opioid dependence, benzodiazepine dependence, anaphalytic shock, seizures, hypoglycemia, neurodegenerative disorders, allergies, blood pressure, acute chest pain, mastocytosis disease, pain management, anxiety, post-traumatic stress disorder, sleep disorders, hypercalcaemia, osteoporosis, migraines, hormone replacement therapy, smoking cessation, nausea, motion sickness, heartburn, indigestion, acid reflux, hemophiliac bleeding, urinary incontinence, mood disorders, vitamin deficiencies, low phosphate levels, diarrhea, asthma, chronic obstructive pulmonary disease, endometriosis, and early puberty; pharmaceutical research and development into treatments of opioid dependence, benzodiazepine dependence, anaphalytic shock, seizures, hypoglycemia, neurodegenerative disorders, allergies, blood pressure, acute chest pain, mastocytosis disease, pain management, anxiety, post-traumatic stress disorder, sleep disorders, hypercalcaemia, osteoporosis, migraines, hormone replacement therapy, smoking cessation, nausea, motion sickness, heartburn, indigestion, acid reflux, hemophiliac bleeding, urinary incontinence, mood disorders, vitamin deficiencies, low phosphate levels, diarrhea, asthma, chronic obstructive pulmonary disease, endometriosis, and early puberty
"THERAPEUTICS"

Trademark Events
Mar 5, 2024
Notice Of Approval Of Extension Request E-Mailed
Mar 2, 2024
Sou Extension 1 Granted
Mar 2, 2024
Sou Extension 1 Filed
Mar 2, 2024
Sou Teas Extension Received
Sep 12, 2023
Noa E-Mailed - Sou Required From Applicant
Jul 18, 2023
Official Gazette Publication Confirmation E-Mailed
Jul 18, 2023
Published For Opposition
Jun 28, 2023
Notification Of Notice Of Publication E-Mailed
Jun 8, 2023
Approved For Pub - Principal Register
May 11, 2023
Teas/Email Correspondence Entered
May 11, 2023
Correspondence Received In Law Office
May 11, 2023
Teas Response To Office Action Received
Apr 14, 2023
Teas Change Of Correspondence Received
Apr 14, 2023
Teas Withdrawal Of Attorney Received-Firm Retains
Apr 14, 2023
Attorney/Dom.Rep.Revoked And/Or Appointed
Apr 14, 2023
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
Apr 11, 2023
Notification Of Non-Final Action E-Mailed
Apr 11, 2023
Non-Final Action E-Mailed
Apr 11, 2023
Non-Final Action Written
Mar 2, 2023
Teas/Email Correspondence Entered
Feb 28, 2023
Correspondence Received In Law Office
Feb 28, 2023
Teas Response To Office Action Received
Aug 31, 2022
Notification Of Non-Final Action E-Mailed
Aug 31, 2022
Non-Final Action E-Mailed
Aug 31, 2022
Non-Final Action Written
Aug 30, 2022
Assigned To Examiner
Nov 24, 2021
New Application Office Supplied Data Entered
Nov 23, 2021
New Application Entered

Trademark Alertz updated from USPTO on 2030-01-24